title: Efficacy of tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma: the Korean Society of Pediatric Hematology-Oncology experience over 6 years (2000-2005).
abstract: The efficacy of tandem high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) was investigated in patients with high-risk neuroblastoma. Patients over 1 yr of age who were newly diagnosed with stage 4 neuroblastoma from January 2000 to December 2005 were enrolled in The Korean Society of Pediatric Hematology-Oncology registry. All patients who were assigned to receive HDCT/ASCR at diagnosis were retrospectively analyzed to investigate the efficacy of single or tandem HDCT/ASCR. Seventy and 71 patients were assigned to receive single or tandem HDCT/ASCR at diagnosis. Fifty-seven and 59 patients in the single or tandem HDCT group underwent single or tandem HDCT/ASCR as scheduled. Twenty-four and 38 patients in the single or tandem HDCT group remained event free with a median follow-up of 56 (24-88) months. When the survival rate was analyzed according to intent-to-treat at diagnosis, the probability of the 5-yr event-free survival+/-95% confidence intervals was higher in the tandem HDCT group than in the single HDCT group (51.2+/-12.4% vs. 31.3+/-11.5%, P=0.030). The results of the present study demonstrate that the tandem HDCT/ASCR strategy is significantly better than the single HDCT/ASCR strategy for improved survival in the treatment of high-risk neuroblastoma patients.
authors.affiliation: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: Ki Woong
authors.initials: KW
authors.lastname: Sung
authors.forename: Hyo Seop
authors.initials: HS
authors.lastname: Ahn
authors.forename: Bin
authors.initials: B
authors.lastname: Cho
authors.forename: Yong-Mook
authors.initials: YM
authors.lastname: Choi
authors.forename: Nack Gyun
authors.initials: NG
authors.lastname: Chung
authors.forename: Tai Ju
authors.initials: TJ
authors.lastname: Hwang
authors.forename: Ho Joon
authors.initials: HJ
authors.lastname: Im
authors.forename: Dae Chul
authors.initials: DC
authors.lastname: Jeong
authors.forename: Hyoung Jin
authors.initials: HJ
authors.lastname: Kang
authors.forename: Hong Hoe
authors.initials: HH
authors.lastname: Koo
authors.forename: Hoon
authors.initials: H
authors.lastname: Kook
authors.forename: Hack Ki
authors.initials: HK
authors.lastname: Kim
authors.forename: Chuhl Joo
authors.initials: CJ
authors.lastname: Lyu
authors.forename: Jong Jin
authors.initials: JJ
authors.lastname: Seo
authors.forename: Hee Young
authors.initials: HY
authors.lastname: Shin
authors.forename: Keon Hee
authors.initials: KH
authors.lastname: Yoo
authors.forename: Sung Chul
authors.initials: SC
authors.lastname: Won
authors.forename: Kun Soo
authors.initials: KS
authors.lastname: Lee
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy / Q000401:mortality; D004358:Drug Therapy / Q000401:mortality*; D005260:Female; D006801:Humans; D007223:Infant; D007723:Korea / Q000453:epidemiology; D008137:Longitudinal Studies; D008297:Male; D009447:Neuroblastoma / Q000401:mortality* / Q000628:therapy*; D015995:Prevalence; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D033581:Stem Cell Transplantation / Q000401:mortality*; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome